Makino Y, Yamanoi A, Kimoto T, El-Assal O N, Kohno H, Nagasue N
Second Department of Surgery, Shimane Medical University, Izumo, Japan.
Am J Gastroenterol. 2000 May;95(5):1294-300. doi: 10.1111/j.1572-0241.2000.02028.x.
This study retrospectively evaluated the association between perioperative blood transfusion and intrahepatic recurrence in patients with hepatocellular carcinoma (HCC) who had undergone curative hepatic resections.
Hepatic resection was performed with curative intent in 195 patients with primary HCC between 1985 and 1996. Patients who had received perioperative blood transfusion (transfused group: n = 117) and those who had no perioperative blood transfusion (nontransfused group: n = 78) were compared in terms of conventional prognostic variables and cancer-free survival by the univariate and multivariate analyses.
The 1-, 3-, and 5-yr cancer-free survival rates in the nontransfused and transfused groups were 83.4% and 67.9%, 43.0% and 36.7%, and 23.1% and 24.6%, respectively (p = 0.175). Multivariate analysis of prognostic factors in all patients revealed that vascular invasion, tumor size (> or =5 cm), and Child's class were independent factors for intrahepatic recurrence. Further analyses in various stratified groups showed that perioperative blood transfusion was an independent predictor of prognosis in HCC patients with portal vein invasion (RR: 2.8, p = 0.0038). The 1-, 3-, and 5-yr survival rates in the nontransfused and transfused groups with portal vein invasion were 71.9% and 41.6%, 54.5% and 10.9%, and 26% and 0%, respectively (p = 0.0003).
We conclude that perioperative blood transfusions enhance the risk of intrahepatic recurrence of HCC in patients with portal vein invasion. As well, the more difficult surgery and the increased manipulation of the liver that occur in these cases create a greater possibility of tumor dissemination.
本研究回顾性评估了接受根治性肝切除术的肝细胞癌(HCC)患者围手术期输血与肝内复发之间的关联。
1985年至1996年间,对195例原发性HCC患者进行了根治性肝切除术。通过单因素和多因素分析,比较了接受围手术期输血的患者(输血组:n = 117)和未接受围手术期输血的患者(未输血组:n = 78)的传统预后变量和无癌生存率。
未输血组和输血组的1年、3年和5年无癌生存率分别为83.4%和67.9%、43.0%和36.7%、23.1%和24.6%(p = 0.175)。对所有患者的预后因素进行多因素分析显示,血管侵犯、肿瘤大小(≥5 cm)和Child分级是肝内复发的独立因素。在不同分层组中的进一步分析表明,围手术期输血是门静脉侵犯的HCC患者预后的独立预测因素(相对风险:2.8,p = 0.0038)。门静脉侵犯的未输血组和输血组的1年、3年和5年生存率分别为71.9%和41.6%、54.5%和10.9%、26%和0%(p = 0.0003)。
我们得出结论,围手术期输血会增加门静脉侵犯的HCC患者肝内复发的风险。此外,这些病例中手术难度增加以及肝脏操作增多,增加了肿瘤播散的可能性。